DOCK7 Antibody

What is DOCK7 and why is it significant in biological research?

DOCK7 is a 242 kDa protein (2109 amino acids) that functions as a guanine nucleotide exchange factor (GEF) for small GTPases Rac1 and Cdc42. It belongs to the atypical Dock180 family of Rho GEFs, which contain two evolutionarily conserved Dock Homology Regions (DHR1 and DHR2) . DOCK7 is highly expressed in major regions of the developing rodent brain, including hippocampus and cortex, and has been shown to control axon formation and myelination through activation of Rac and both Rac and Cdc42, respectively . Additionally, DOCK7 has emerged as a critical regulator of interkinetic nuclear migration (INM) in radial glial cells (RGCs) and plays an important role in breast cancer cell survival .

What are the key specifications of available DOCK7 antibodies?

Based on current research resources, two major DOCK7 antibodies are widely used:

Both antibodies are stored in liquid form with specific buffer conditions (PBS with glycerol and sodium azide) and have been validated across multiple cell lines and tissue samples .

What cellular and tissue samples have DOCK7 antibodies been validated in?

The Proteintech DOCK7 antibody (13000-1-AP) has undergone extensive validation across multiple sample types:

Positive Western Blot detection in:

• Human cell lines: HEK-293T, Jurkat, HeLa, HepG2, K-562

• Animal tissues: Mouse brain, human brain, mouse ovary, rat brain

Positive Immunoprecipitation in:

• HeLa cells

Positive Immunofluorescence/ICC in:

• HeLa cells

These validations help researchers select appropriate experimental models when studying DOCK7 functions.

What are the recommended dilutions and protocols for DOCK7 antibody applications?

Optimal antibody dilutions vary by application:

For all applications, it's recommended to titrate the antibody in each testing system to obtain optimal results, as performance can be sample-dependent .

How should I optimize Western blot protocols for detecting DOCK7?

DOCK7 is a high molecular weight protein (~242 kDa), requiring specific optimization for effective detection:

• Gel preparation: Use low percentage (6-8%) SDS-PAGE gels to properly resolve large proteins

• Transfer conditions: Implement extended transfer times (overnight at low voltage) or use specialized transfer systems designed for high molecular weight proteins

• Blocking: Use 5% non-fat dry milk or BSA in TBS-T for 1 hour at room temperature

• Primary antibody incubation: Dilute according to manufacturer recommendations (1:5000-1:50000 for Proteintech antibody) and incubate overnight at 4°C

• Controls: Include positive controls such as HeLa cells, HEK-293T cells, or brain tissue lysates which consistently show DOCK7 expression

The expected molecular weight range for DOCK7 is 238-243 kDa, which serves as a validation marker for specific detection .

What methods are most effective for studying DOCK7's protein interactions?

Co-immunoprecipitation (Co-IP) has proven particularly effective for studying DOCK7's protein interactions. Research has demonstrated that:

• Immunoprecipitation efficiency: The Proteintech DOCK7 antibody effectively immunoprecipitates endogenous DOCK7 from HeLa cells

• Documented interactions: Co-IP experiments have successfully demonstrated DOCK7's interactions with:

  • TACC3 (microtubule-associated protein)

  • TSC1 and TSC2 (mTOR pathway regulators)

  • mTOR itself

  • AKT

  • Rheb

When performing Co-IP for DOCK7, researchers should prepare cell lysates in non-denaturing conditions and use 0.5-4.0 μg of DOCK7 antibody per 1.0-3.0 mg of total protein lysate to maximize interaction detection .

How can I investigate DOCK7's role in neuronal development?

DOCK7 plays critical roles in neuronal development through multiple mechanisms. To study these functions:

• Interkinetic nuclear migration (INM) assessment:

  • Utilize brain section immunostaining with anti-DOCK7 antibodies alongside markers for radial glial cells (RGCs)

  • Implement live imaging of neural progenitors to track nuclear movement following DOCK7 manipulation

• DOCK7-TACC3 interaction analysis:

  • Examine microtubule dynamics in the presence of DOCK7 and/or TACC3 using immunofluorescence

  • Investigate if DOCK7 antagonizes TACC3's microtubule growth-promoting function through co-localization studies

• Neuronal differentiation studies:

  • Monitor the generation of basal progenitors (BPs) and neurons from RGCs following DOCK7 knockdown or overexpression

  • Evaluate axon formation processes, as DOCK7 has been shown to control this through Rac activation

Research findings indicate that DOCK7 influences neurogenesis by controlling basolateral-to-apical interkinetic nuclear migration of RGCs, and importantly, this function does not involve its GEF activity but instead requires interaction with TACC3 .

What approaches should I use to study DOCK7's roles in cancer progression?

DOCK7 has been implicated in cancer cell survival and progression, particularly in breast cancer. Effective research approaches include:

• Expression analysis in cancer subtypes:

  • Evaluate DOCK7 expression across cancer cell lines and patient samples

  • Note that DOCK7 is highly expressed in triple-negative breast cancers

• Functional assays following DOCK7 manipulation:

  • Anchorage-independent growth: Colony formation in soft agar has shown dramatic decreases following DOCK7 knockdown in multiple cancer cell lines including:

    • Receptor-positive breast cancer cells (SKBR3, MCF7)

    • Triple-negative breast cancer cells (MDA-MB-231)

    • Cervical carcinoma cells (HeLa)

    • Lung carcinoma cells (A549)

• Survival studies under stress conditions:

  • Challenge cells with serum-free media for extended periods (e.g., four days)

  • Research shows DOCK7 knockdown cells have significantly compromised ability to survive in the absence of nutrients compared to control cells

• Analysis of DOCK7 interaction with cancer-associated signaling pathways:

  • Investigate DOCK7's interaction with the mTOR/AKT pathway components:

    • Co-immunoprecipitation with TSC1/2, mTOR, AKT, and Rheb

    • Assessment of mTOR signaling activity following DOCK7 manipulation

How can I evaluate the specificity of my DOCK7 antibody detection?

Ensuring antibody specificity is critical for reliable research outcomes. Implement these validation approaches:

• Genetic validation:

  • Utilize DOCK7 knockdown via shRNA in cells known to express DOCK7 (e.g., MDA-MB-231, HeLa, A549)

  • Compare antibody signal in control vs. knockdown samples across all intended applications (WB, IF, IP)

• Multiple antibody comparison:

  • Compare detection patterns using different antibodies targeting distinct DOCK7 epitopes

  • Consistent detection across antibodies strengthens confidence in specificity

• Cross-reactivity assessment:

  • Test antibody reactivity in samples from multiple species (human, mouse, rat)

  • Evaluate detection in tissues known to express DOCK7 (brain) versus those with lower expression

• Positive control inclusion:

  • Use validated positive controls in each experiment:

    • HEK-293T cells, mouse brain tissue, human brain tissue, Jurkat cells, HeLa cells

• Blocking peptide experiments:

  • Where available, use the immunizing peptide to compete with and block specific binding

  • The Boster antibody offers a blocking peptide option for specificity validation

Why might I observe variability in DOCK7 detection across different experimental systems?

Several factors can contribute to variability in DOCK7 detection:

• Expression level variations:

  • DOCK7 expression differs significantly across tissues and cell types

  • Highest expression is typically observed in brain tissue and certain cancer cell lines

• Protein complexes and interactions:

  • DOCK7 forms complexes with multiple proteins (TACC3, TSC1/2, mTOR, AKT)

  • These interactions may mask epitopes in different cellular contexts

• Technical considerations for high molecular weight proteins:

  • Inefficient transfer during Western blotting

  • Insufficient denaturation or extraction from cellular compartments

  • Proteolytic degradation during sample preparation

• Antibody-specific detection capabilities:

  • Different antibodies target distinct epitopes that may be differentially accessible

  • Some antibodies may detect specific post-translational modifications or conformational states

When encountering variability, systematically adjust sample preparation, antibody concentration, and detection methods while including appropriate positive controls.

How should I interpret DOCK7's functional roles based on antibody-derived data?

When interpreting DOCK7 functions from antibody-based experiments, consider:

The current body of research indicates DOCK7 functions beyond its canonical GEF activity, with important roles in microtubule regulation and cellular signaling pathways that contribute to both developmental processes and cancer progression .

What critical controls should I include when studying DOCK7 using antibody-based methods?

Robust experimental design requires appropriate controls:

• For Western blot analysis:

  • Positive controls: Include lysates from validated DOCK7-expressing cells (HeLa, HEK-293T, brain tissue)

  • Negative controls: Include DOCK7 knockdown samples

  • Loading controls: Use appropriate housekeeping proteins, considering DOCK7's high molecular weight

  • Molecular weight markers: Ensure detection at the expected 238-243 kDa range

• For immunofluorescence/immunocytochemistry:

  • Primary antibody controls: Include samples without primary antibody to assess secondary antibody background

  • Knockdown controls: Compare staining patterns in DOCK7-depleted cells

  • Co-staining with known markers: Validate expected subcellular localization

• For co-immunoprecipitation studies:

  • Input controls: Analyze a portion of pre-IP lysate

  • IgG controls: Use matched isotype IgG for non-specific binding assessment

  • Reciprocal IP: When possible, perform reverse IP (pull down interacting partner, detect DOCK7)

  • Negative controls: Include samples lacking the expected interaction partner

• For functional studies:

  • Multiple shRNA/siRNA constructs: Use at least two independent targeting sequences

  • Rescue experiments: Restore function with shRNA-resistant DOCK7 expression

  • Positive phenotypic controls: Include manipulations with known outcomes in your experimental system

How might recent advances in antibody technologies enhance DOCK7 research?

Emerging antibody technologies offer new opportunities for DOCK7 research:

• Single-domain antibodies and nanobodies:

  • Smaller size allows access to restricted epitopes

  • Potential for improved detection of DOCK7 in complex with interacting partners

  • May enable live-cell imaging of DOCK7 dynamics

• Proximity labeling methods:

  • Antibody-guided proximity labeling (BioID, APEX) could reveal the complete DOCK7 interactome

  • Would expand on known interactions with TACC3, TSC1/2, mTOR, and AKT

• Antibody-based degradation technologies:

  • Targeted protein degradation (e.g., PROTAC, dTAG) combined with specific antibodies

  • Could provide acute, reversible manipulation of DOCK7 levels

  • May overcome limitations of genetic knockdown approaches

• Phospho-specific antibodies:

  • Development of antibodies against phosphorylated DOCK7 would enable studies of its regulation

  • Could reveal how DOCK7 activity is controlled in different cellular contexts

These technologies would complement current approaches and potentially overcome existing research limitations.